This article is more than 5 years old. Information may no longer be current.
VIDEO: Additional research necessary to define role of PARP inhibitors for BRCA–mutated breast cancer
Click Here to Manage Email Alerts
SAN ANTONIO — Jame Abraham, MD, director of the breast oncology program at Cleveland Clinic, offers perspective on the BROCADE study results presented at the San Antonio Breast Cancer Symposium.
Researchers of the randomized phase 2 study evaluated the addition of veliparib (ABT-888, AbbVie) — a selective inhibitor of PARP-1 and PARP-2 — to carboplatin and paclitaxel or to temozolomide in patients with BRCA1– or BRCA2–mutated locally recurrent or metastatic breast cancer.
“PARP inhibitors are probably one of the most exciting compounds in breast cancer at this point,” Abraham said.
The addition of veliparib to carboplatin and paclitaxel did not significantly extend PFS or OS; however, the combination significantly increased overall response rate.
“I think we need to continue to do studies to find out what is the right dose, what is the right combination and making sure that this combination of these three agents is not affecting the quality of life for the patients,” Abraham added. – by Kristie L. Kahl
Reference:
Han HS, et al. Abstract S2-05. Presented at: San Antonio Breast Cancer Symposium; Dec. 7-9, 2016; San Antonio.
Disclosure: Abraham reports no relevant financial disclosures.